Richard Stewart, MD
Ophthalmology · Boulder, CONPI 1932113578
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 225 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations.
Across 225 payments — averaging $21.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$987
- Alcon$780
- Sight Sciences, Inc.$690
- Bausch & Lomb Americas Inc.$575
- Mallinckrodt Hospital Products Inc.$391
- Rxsight Inc$272
- plus $1K from 16 others
What the payments were for
- Food & beverage$4,892100%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 49 | $987 |
| Alcon | 59 | $780 |
| Sight Sciences, Inc. | 14 | $690 |
| Bausch & Lomb Americas Inc. | 30 | $575 |
| Mallinckrodt Hospital Products Inc. | 16 | $391 |
| Rxsight Inc | 2 | $272 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $172 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $151 |
| Dompe US, Inc. | 5 | $115 |
| Thea Pharma Inc. | 6 | $105 |
| Aerie Pharmaceuticals, Inc. | 5 | $105 |
| Biotissue Holdings Inc. | 5 | $94 |
| Kala Pharmaceuticals, Inc. | 4 | $93 |
| Akorn Operating Company LLC | 5 | $86 |
| Novartis | 3 | $62 |
| Ivantis, Inc | 2 | $48 |
| Nova Eye, Inc. | 1 | $45 |
| Amgen | 2 | $40 |
| Regeneron Healthcare Solutions, Inc. | 1 | $33 |
| Rayner Intraocular Lenses Limited | 1 | $26 |
| Sun Pharmaceutical Industries Inc. | 1 | $21 |
| Eyevance Pharmaceuticals LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,910 in reported general payments places this provider in the 80th percentile of 262 ophthalmology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyzultaLatanoprostene Bunod | 103 | $42,023 |
| LumiganBimatoprost | 88 | $40,788 |
| XiidraLifitegrast | 16 | $26,319 |
| CombiganBrimonidine Tartrate/Timolol | 49 | $17,966 |
| Prednisolone Acetate | 215 | $10,723 |
| RocklatanNetarsudil Mesylat/Latanoprost | 29 | $10,055 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 54 | $9,983 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 32 | $8,481 |
| RhopressaNetarsudil Mesylate | 20 | $6,512 |
| TafluprostTafluprost/Pf | 19 | $6,181 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 25 | $3,698 |
| Travoprost | 22 | $3,623 |
| AlrexLoteprednol Etabonate | 11 | $3,419 |
| Timolol Maleate | 140 | $3,387 |
| Latanoprost | 341 | $3,271 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $575 | $68,342119 claims |
| AbbVieLumigan, Combigan | $987 | $58,754137 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $105 | $16,56749 claims |
| AlconSimbrinza | $780 | $8,48132 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCAlrex | $151 | $3,41911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 262 ophthalmology providers in Colorado.
Other ophthalmology in Boulder
- Mark PackerBoulder$3.5M
- Geeta Lalchandani LalwaniBoulder$319K
- Jon DishlerGreenwood Village$1M
- Mark DaceyDenver$370K
- Cristos IfantidesDenver$343K
- Richard DavidsonAurora$316K
- Steven DeweyColorado Springs$246K
- Jack ZamoraDenver$172K
- Eva KimDenver$95K
- Michael JansenDenver$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.